CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (NASDAQ:CERS) announced today that LifeShare Blood
Centers has signed a purchase agreement for the INTERCEPT Blood System,
a pathogen reduction technology, for platelets and plasma. LifeShare
Blood Centers supplies approximately 16,000 platelet and 79,000 plasma
units for patient transfusion annually as the sole provider of blood
products to more than 100 medical facilities throughout Louisiana, East
Texas, and Southern Arkansas.
LifeShare’s Executive Management team stated that their number one
priority is to ensure the safety of their blood supply. By incorporating
the INTERCEPT Blood System into their operations, pathogen reduction
will provide an added layer of protection against potentially harmful
pathogens and has the potential to increase availability and utilization
of platelets.
Founded in Shreveport, Louisiana in 1942, LifeShare is a nonprofit
community blood center providing quality blood products and related
service for use by patients. LifeShare is a member of America’s Blood
Centers and the American Rare Donor Program, is licensed by the U.S.
Food & Drug Administration, and accredited by AABB.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field
of blood transfusion safety. The INTERCEPT Blood System is designed to
reduce the risk of transfusion-transmitted infections by inactivating a
broad range of pathogens such as viruses, bacteria and parasites that
may be present in donated blood. The nucleic acid targeting mechanism of
action of the INTERCEPT treatment is designed to inactivate established
transfusion threats, such as Hepatitis B and C, HIV, West Nile Virus and
bacteria, as well as emerging pathogens such as chikungunya, malaria and
dengue. Cerus currently markets and sells the INTERCEPT Blood System for
both platelets and plasma in the United States, Europe, the Commonwealth
of Independent States, the Middle East and selected countries in other
regions around the world. The INTERCEPT red blood cell system is in
clinical development. See www.cerus.com
for information about Cerus.
INTERCEPT and INTERCEPT Blood System are trademarks of Cerus Corporation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160107005403/en/
Source: Cerus Corporation